Search
Interviews with the world’s key opinion leaders in cancer
Jan Burger

New drug looks very promising in high risk chronic lymphocytic leukaemia

Jan Burger
AudioMedica News
New drug looks very promising in high risk chronic lymphocytic leukaemia
Loading
/

ATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of Hematology annual meeting. Dr Jan Burger from the MD Anderson Cancer Center in Houston, Texas, told Peter Goodwin about the results of using it in combination with rituximab.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/121209JanBurgerPODCASTLoRes.mp3]

Further reading